Outsourced Pharma Capacity Update Videos - Cell & Gene

  1. VintaBio Capacity Update July 2024: Cell & Gene Therapy 8/14/2024

    VintaBio has created open capacity for AAV clinical manufacturing through its streamlined VintaProcess platform which is an intensified adherent AAV process with very low impurities.

  2. FUJIFILM Diosynth Biotechnologies Capacity Update July 2024: Cell & Gene Therapy 8/14/2024

    The capacity expansion project at our Thousand Oaks facility will add new cleanrooms, updated development labs, expanded QC labs, and high efficiency warehousing solutions.

  3. Minaris Advanced Therapies Capacity Update July 2024: Cell & Gene Therapy 8/14/2024

    Learn how our expert and experienced team in Philadelphia supports cell therapy and viral vector production across a variety of modalities and stages of clinical and commercial manufacturing.

  4. Alcami Capacity Update July 2024: Cell & Gene Therapy 8/14/2024

    Alcami offers method development, method validation and QC testing, as well as R&D testing support, leveraging our company’s extensive expertise in various testing platforms.

  5. Andelyn Biosciences Capacity Update July 2024: Cell & Gene Therapy 8/14/2024

    To address the myriad of challenges that accompany AAV manufacturing, Andelyn uses a combination of reductionist and holistic approaches to perform end-to-end optimization for its platform.

  6. Capacity Update July 2024: Cell & Gene Therapy 8/14/2024

    In addition to the immediate capacity for Draw-to-Thaw™ services in New York, NY, and Louisville, KY, we have openings for process and analytical development work in its Houston, TX facility.

  7. Cellistic Capacity Update July 2024: Cell & Gene Therapy 8/14/2024

    Explore the latest insights and challenges in the cell therapy space, and learn how Cellistic overcomes these challenges with iPSC, focusing on regulatory strategies and cutting-edge capabilities.

  8. ElevateBio Capacity Update July 2024: Cell & Gene Therapy 7/25/2024

    Partner with ElevateBio BaseCamp to leverage the LentiPeak™ platform for high-quality, scalable lentiviral vector production and accelerate your cell and gene therapy development.

  9. Resilience Capacity Update May 2024: Cell & Gene Therapy 6/13/2024

    With a strong network of 11 sites located across North America supporting 5 modalities, Resilience provides innovative solutions and services for established and emerging therapies.

  10. ReciBioPharm Capacity Update May 2024: Cell & Gene Therapy 6/13/2024

    Learn more about our global capabilities in Nucleic Acid, AAV, Lentivirus, Microbiome and Fill-Finish. We offer end-to-end GMP manufacturing under one roof through an integrated supply chain.